Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Recurrence 1Medulloblastoma 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × NVP-LEQ506 × Clear all
NCT01106508 2020-12-17

A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
57 enrolled
CNSDermatologic

Carcinoma, Basal Cell, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡